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Abstract
Background: While protease-activated-receptor 1 (PAR1) plays a central role in tumor progression, little is known about the
cell signaling involved.
Methodology/Principal Findings: We show here the impact of PAR1 cellular activities using both an orthotopic mouse
mammary xenograft and a colorectal-liver metastasis model in vivo, with biochemical analyses in vitro. Large and highly
vascularized tumors were generated by cells over-expressing wt hPar1, Y397Z hPar1, with persistent signaling, or Y381A
hPar1 mutant constructs. In contrast, cells over-expressing the truncated form of hPar1, which lacks the cytoplasmic tail,
developed small or no tumors, similar to cells expressing empty vector or control untreated cells. Antibody array
membranes revealed essential hPar1 partners including Etk/Bmx and Shc. PAR1 activation induces Etk/Bmx and Shc binding
to the receptor C-tail to form a complex. Y/A mutations in the PAR1 C-tail did not prevent Shc-PAR1 association, but
enhanced the number of liver metastases compared with the already increased metastases obtained with wt hPar1.W e
found that Etk/Bmx first binds via the PH domain to a region of seven residues, located between C378-S384 in PAR1 C-tail,
enabling subsequent Shc association. Importantly, expression of the hPar1-7A mutant form (substituted A, residues 378-
384), which is incapable of binding Etk/Bmx, resulted in inhibition of invasion through Matrigel-coated membranes.
Similarly, knocking down Etk/Bmx inhibited PAR1-induced MDA-MB-435 cell migration. In addition, intact spheroid
morphogenesis of MCF10A cells is markedly disrupted by the ectopic expression of wt hPar1. In contrast, the forced
expression of the hPar1-7A mutant results in normal ball-shaped spheroids. Thus, by preventing binding of Etk/Bmx to PAR1
-C-tail, hPar1 oncogenic properties are abrogated.
Conclusions/Significance: This is the first demonstration that a cytoplasmic portion of the PAR1 C-tail functions as a scaffold
site. We identify here essential signaling partners, determine the hierarchy of binding and provide a platform for therapeutic
vehicles via definition of the critical PAR1-associating region in the breast cancer signaling niche.
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Introduction
Protease-activated receptor-1 (PAR1), a G protein-coupled receptor
(GPCR), is the first and prototype member of the mammalian PAR
family, which comprises four genes. The activation of PAR1
involves the release of an N-terminal peptide and the exposure of an
otherwise hindered ligand, resulting in an exclusive mode of
activation and a general paradigm for the entire PAR family (1–3).
While a well-known classical observation points to a tight link
between hyper-activation of the coagulation system and cancer
malignancies, the molecular mechanism that governs pro-coagulant
tumor progression remains poorly defined [1,2,3]. Surprisingly, the
zinc-dependent matrix-metalloprotease 1 (MMP-1), a collagenase
that efficiently cleaves extracellular matrix (ECM) and basement
membrane components, has been shown to specifically activate
PAR1 [4]. The PAR1 -MMP1 axis may thus provide a direct
mechanistic link between PAR1 and tumor metastasis.
Levels of hPar1 expression and epithelial tumor progression are
correlated in both clinically obtained biopsy specimens and a wide
spectrum of differentially metastatic cell lines [5,6]. PAR1 also
plays a role in the physiological invasion process of placental
cytotrophoblasts during implantation into the uterus decidua [7].
Trophoblast invasion shares many features with the tumor cell
invasion process; it differs, however, by the time-limited hPar1
expression, which is confined to the trophoblast-invasive period,
and is shut off immediately thereafter, when the need to invade
disappears [7]. This provides strong support for the idea that the
hPar1 gene is part of an invasive gene program.
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appear to occur in a different mode than other GPCRs. Instead of
recycling back to the cell surface after ligand stimulation, activated
PAR1 is sorted to the lysosomes and degraded [8,9]. Aberrant
PAR1 trafficking, resulting in receptor-populated cell surfaces and
causing prolonged and persistent signals, has been found in breast
cancer [10]. While cellular trafficking of PAR1 impinges on the
extent and mode of signaling, identification of individual PAR1
signaling partners and their contribution to breast cancer
progression remain to be elucidated.
In the present study, we have identified PAR1 C-tail as a
scaffold site for the immobilization of signaling partners. In
addition to identifying key partners, we have determined the
hierarchy of binding and established a region in PAR1 C-tail
critical for breast cancer signaling. The association of Etk/Bmx
and Shc to form a physical complex with PAR1 C-tail is
demonstrated. The prime link of Etk/Bmx to PAR1 is mediated
via its PH domain, enabling the subsequent immobilization of Shc.
The physiological significance of PAR1-Etk/Bmx binding is
emphasized by the inhibition of Matrigel invasion and appearance
of nearly intact acini morphogenesis of polarized cell architecture
when this site is mutated. The use of consecutive A residues
inserted into the proposed Etk/Bmx binding region of PAR1 C-tail
(e.g., hPar1-7A) abolished PAR1 -induced pro-oncogenic proper-
ties. Thus, by preventing the binding of a key signaling partner to
PAR1 C-tail, efficient inhibition of PAR1 -induced tumor-
associated functions, including loss of epithelial cell polarity,
migration and invasion through basement membranes, is ob-
tained. Elucidation of the PAR1 C-tail binding domain may
provide a platform for new therapeutic vehicles in treating breast
cancer.
Results
PAR1-enhanced tumor growth and angiogenesis in vivo
is abrogated in the presence of a truncated PAR1 form
To investigate the role of PAR1 signaling in breast tumor
growth and vascularization in vivo, we over-expressed wt hPar1
and deletion constructs [e.g., L369Z, which lacks the entire
cytoplasmic tail, and Y397Z, which exhibits persistent signaling
due to impaired internalization [11,12]] in MCF7 cells. The
functional outcome of MCF7 cells over-expressing various hPar1
constructs in vivo was assessed by orthotopic mammary fat pad
tumor development (proper expression and characterization of
t h ep l a s m i d sa r es h o w ni nF i g u r eS 1 ) .M C F 7c e l l so v e r -
expressing either Y397Z or wt hPar1 constructs (e.g., MCF7/
Y397Z hPar1;M C F 7 / wt hPar1) markedly enhanced tumor
growth in vivo following implantation into the mammary glands
(Fig. 1C and D), whereas MCF7 cells over-expressing truncated
hPar1 behaved similar to control MCF7 cells in vector-injected
mice, which developed only very small tumors (Fig. 1C). The
tumors obtained with MCF7/wt hPar1 and MCF7/Y397Z hPar1
were 5 and 5.8 times larger, respectively, than tumors produced
by the MCF7/empty vector-transfected cells. Histological
examination (H&E staining) showed that while both MCF7/wt
hPar1 and MCF7/Y397Z hPar1 tumors infiltrated into the fat pad
t i s s u e so ft h eb r e a s t ,t h eM C F 7 / Y397Z hPar1 tumors further
infiltrated the abdominal muscle (Fig. 1D). In contrast, tumors
produced by empty vector or truncated hPar1-transfected cells
were capsulated, with no obvious cell invasion. Proliferation
levels were evaluated by immunostaining with Ki-67 and were 3
times higher in Y397Z hPar1 or wt hPar1 tumors (Fig. 2) than in
the small tumors produced by either empty vector or truncated
hPar1-transfected cells (p,0.0001, Fig. 2B). Tumor growth can
also be attributed to blood vessel formation [13,14]. The hPar1-
induced breast tumor vascularization was assessed by immuno-
staining with anti-lectin- and anti-CD31 antibodies. Both
MCF7/Y397Z and MCF7/wt hPar1 tumors were intensely
stained (Fig. 2A; Bii and iii). In contrast, only a few blood
vessels were found in the small tumors of empty vector or
truncated hPar1 (Fig. 2A; Bii and iii). Thus, both MCF7/wt hPar1
and MCF7/Y397Z hPar1 cells were shown to effectively induce
breast tumor growth, proliferation and angiogenesis, while the
MCF7/truncated hPar1 and MCF7/empty vector-expressing
cells had no significant effect.
PAR1 C-tail binds the Shc adaptor protein
To identify proteins that associate with the PAR1 C-terminus
and participate in the tumor signaling pathway, we fused the
cytoplasmic tail of hPar1 to a GST protein and used the construct
as ‘‘bait’’ to specifically detect associated proteins. Lysates
obtained from a highly metastatic breast carcinoma line (e.g.,
MDA-MB-435 cells) were assessed for binding to the GST- PAR1
C-tail column. Amino acid sequence analysis of proteins bound to
the column repeatedly indicated the presence of the Shc adapter
protein. Indeed, application of MDA-MB-435 cell lysates onto a
GST- PAR1 C-tail column or a GST control column showed the
three Shc isoforms specifically bound to the GST- PAR1 -C-tail
column, but not to the GST control column (Fig. 3A). Shc
isoforms refer to a series of proteins (e.g., 66, 52 and 46 kDa)
termed Shc (Src homology 2/a-collagen–related) [15,16]. cDNA
analyses of the family proteins has demonstrated that the 46- and
52-kDa species arise from alternative translation initiation sites
within the same transcript, giving rise to a 59-amino acid terminal
truncation of the 46-kDa isoform compared to the 52-kDa
isoform. In contrast, the 66-kDa species most likely arises from
an alternatively spliced message since there is only one Shc gene
and the carboxy terminal antibodies cross react with all three
molecular weight species. Co-immunoprecipitation studies using
either PAR1 (Fig. 3B) or Shc antibodies (Fig. 3C) confirmed the
PAR1 -Shc association 5 min after TFLLRNPNDK activation;
this association remained high during the 30 min of analysis
(Fig. 3B and C). The Shc protein comprises multiple protein
docking sites, including SH2, phospho-tyrosine binding site (PTB)
and collagen homology domains 1 and 2 (CH1, CH2). When a
GST-Shc-SH2 domain pull-down assay was used following
loading with PAR1 activated MDA-MB-435 cell lysates, we
obtained PAR1 -specific binding to the Shc-SH2 domain. In
contrast, when the tandem SH2 domain from an irrelevant protein
was used as a control, no binding of PAR1 was observed (Fig. 3D).
While searching for the PAR1 C-tail putative tyrosine residues
capable of undergoing phosphorylation and serving as possible
binding sites for the Shc protein (NetPhos 2.0 server), we found four
candidates: Y381,Y 383,Y 397,Y 420 (Fig. 3Ei and ii). Of these, only
three were predicted to undergo phosphorylation: Y381,Y 397 and
Y420 (Fig. 3Eii). Since our preliminary data showed that Y397Z
hPar1 was potent in signaling (Figs 1 and 2) and able to associate
with Shc when transiently expressed in COS-1 cells (data not
shown), we postulated that the Shc binding site(s) in the PAR1 C-
tail is/are located upstream of tyrosine 397. Indeed, sequence
alignment of PAR1 C-tail in nine different species demonstrates
several highly conserved regions (data not shown), among which
are the Y381VY383 residues. Replacement of the relevant tyrosine
(Y) residues upstream to Y397Z hPar1 with alanine (Ala, A) (e.g.,
Y381Ao rY 383A and the double mutant Y381A&Y 383A) did not
prevent the recruitment and physical association between Shc and
PAR1 (for more details see section of ‘‘Hierarchy of binding’’,
bellow).
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We further demonstrated the functionality of the Y381A hPar1
mutant in vivo using a colorectal-liver metastasis model (18), which
provides a rapid metastatic model of liver foci formation. Mouse
CT-26 colon carcinoma cells were genetically engineered to over-
express wt hPar1, Y381A hPar1 or empty vector constructs. These
over-expressing cells were injected intra-splenically into CB6F1
mice (either PAR1 -activated or not) to generate liver metastases.
Tumor growth kinetics and liver metastatic foci appearance were
monitored twice a week by MRI. Both wt hPar1 and Y381A hPar1
enhanced liver metastatic foci formation, compared to control CT-
26 cells. Furthermore, mice inoculated with cells expressing Y381A
hPar1 showed especially extensive and rapid appearance of liver
metastasis as compared to mice inoculated with cells over-
expressing wt hPar1 (Fig. 4). Representative MRI images (Fig. 4A)
of excised livers and histological sections (Fig. 4B), obtained on day
16, demonstrated high metastatic potential of both activated Y381A
hPar1 and wt hPar1. An elevated number of metastatic foci were
observed with the wt hPar1 after PAR1 activation (Fig. 4A), and an
even more dramatic increase was obtained with the activated
Y381A hPar1 construct (Fig. 4A, C). Quantification of liver
metastasis as a function of time is shown in Figure 4C. These
results emphasized that the Y381A hPar1 mutated construct is at
least as functional as the wt hPar1, and the substitution of Y to A
did not impair the ability of hPar1 to initiate signaling and
therefore result in metastasis. The results may further suggest that
Shc does not bind directly to PAR1 C-tail, since replacement of a
key tyrosine residue by alanine (Y381A) does not impair PAR1
function as manifested by metastatic foci formation. It is thus
postulated that whereas Shc is not associated with PAR1 via the
traditional tyrosine-phosphorylated-SH2 complex formation, it
probably involves a third mediator connecting with PAR1. The
molecular mechanism of Y381A hPar1-enhanced liver metastasis
remains to be fully elucidated.
Antibody-array for protein-protein interactions reveals
signaling candidates
To detect the putative mediator(s) linking PAR1 to potential
signaling proteins, we examined custom-made antibody-array
membranes. For this purpose, aggressive breast carcinoma MDA-
MB-435 cells (with high hPar1 levels) were incubated with the
antibody-array membranes before and after PAR1 activation (15
minutes). This identified several activation-dependent proteins
which interact with PAR1, including ICAM, c-Yes, Shc and Etk/
Figure 1. PAR1 enhances tumor growth and angiogenesis in a xenograft mouse model. Ai. Schematic representation of the hPar1
constructs. wt hPar1, truncated hPar1 (devoid of the cytoplasmic tail), Y397Z hPar1 (shorter C-tail of persistent signaling). Aii. Semi-quantitative RT-PCR
analysis of various hPar1 constructs. RT-PCR analysis of cells transfected with wt hPar1, Y397Z hPar1, truncated hPar1 or empty vector using primers to
PAR1 N-terminus (upper panel), C-terminus (middle panel), or GAPDH (lower panel). PAR1 N-terminus primers were as follows: hPar1-sense: 59-
CTCGTCCTCAAGGAGCAAAC-39, antisense orientation: 59-TGGGATCGGAACTTTCTTTG-3’ (564-bp PCR product). PAR1 C-tail primers – sense: 59-TAC TAT
TAC GCT GGA TCC TCT GAG-39 and antisense: 59-CTT GAA TTC CTA AGT TAA CAGCTT-39. These primers give rise to a 181-bp product corresponding
to the entire PAR1 C-tail site, as follows: YY – YASSECQRYVYSILCCKESSDPSYNSSGQLMASKMDTCSSNLNNSIYKKLLT. B. Western blot analyses of MCF7
cells expressing various hPar1 constructs. a. Mock-transfected MCF7; b. Y397Z hPar1; c. Truncated hPar1;d .wt hPar1. C. Mouse mammary tumor growth
in animals implanted with cells expressing wt hPar1 and variants. MCF7 cells expressing various hPar1 were inoculated into the mammary pads of mice.
Tumor volumes (mean 6 SD) are shown for wt hPar1 (&), Y397Z hPar1 (%), truncated hPar1 (D), and empty vector (m; tumor volume 3063m m
3)
(* P,0.005). D. Morphological appearance. The Y397Z hPar1 and wt hPar1 constructs exhibited intense vascularization and appeared reddish as
opposed to the pale appearance of tumors generated by either empty vector or truncated hPar1. Tissue sections of tumors were stained with H&E
(right panels). Magnification is 6100.
doi:10.1371/journal.pone.0011135.g001
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Etk/Bmx and Shc.
The epithelial tyrosine kinase (Etk), also known as Bmx, is a
non-receptor tyrosine kinase that is unique by virtue of being able
to interact with both tyrosine kinase receptors and GPCRs [17].
This type of interaction is mainly attributed to the pleckstrin
homology (PH) which is followed by the Src homology SH3 and
SH2 domains and a tyrosine kinase site [18]. Etk/Bmx- PAR1
interactions were characterized by binding lysates exhibiting
various hPar1 forms to GST-Etk/Bmx. While Y397Z hPar1 and
wt hPar1 showed specific association with Etk/Bmx, lysates of
truncated hPar1 or JAR cells (lacking PAR1) exhibited no binding
(Fig. 5A). In order to substantiate the physical association between
PAR1 C-tail and Etk/Bmx-PH domain we proteolytically cleaved
the C-tail portion of both wt- and Y381A hPar1-modified tail and
applied the purified fragments onto a GST-PH Etk/Bmx column.
Specific binding was observed with both the wt hPar1 and Y381A
hPar1 purified C-tails (Fig. 5B). Next, we analyzed various
modified PAR1-GST-C tail constructs (e.g., wt hPar1, Y381A hPar1
and Y383A hPar1) for binding to either wt- or kinase-inactive Etk/
Bmx (KQ) cell lysates [18,19]. A tight association between the
PAR1 C-tail and Etk/Bmx was obtained, independent of whether
wt hPar1 or the Y/A mutant forms of PAR1 C-tail were examined.
This was true for both wt- and KQ-Etk mutant (Fig. 5C).
Differential expression of Etk/Bmx in breast biopsies
PAR1 is highly expressed in breast carcinoma specimens, but
not in normal breast tissue, as evidenced by in situ hybridization
analyses [5,20]. Immunohistochemical staining of PAR1 tissue
sections confirms the earlier described RNA riboprobe analysis for
hPar1. Invasive carcinoma specimens were selected from infiltrat-
ing ductal carcinoma (IDC) of high nuclear grade and with
evidence of vascular invasion and lymph node metastases.
Immunohistological analyses of both PAR1 and Etk/Bmx showed
little staining in comedo DCIS and ductal carcinoma in situ, but
high levels of staining in IDC and lobular carcinoma (Fig. 5D;
Figure 2. Proliferation and blood vessel formation in tumors produced by hPar1 constructs. A. Sections of tumors generated by various
hPar1 constructs were subjected to immunohistochemical staining with Ki-67 for proliferation (upper panel), and with either an endothelial cell-
specific lectin or anti-CD31 to visualize blood vessels (lower panel). Bi. Ki-67-positive cells were counted in five microscope fields per tumor section,
and the mean (6 SD) number of cells per high power field (HPF) was determined. Significantly, fewer Ki-67-positive cells were observed in tumors
produced by the empty vector or truncated hPar1 constructs than with wt hPar1 or Y397Z hPar1. Bii and iii. Anti-lectin- or anti-CD31-stained cells,
respectively, were counted as described in (Bi). The morphometric analysis used to evaluate proliferation and blood vessels was performed as
explained in Materials& Methods under the section of histological evaluation and scoring. Briefly, the microscope was calibrated with a micrometer
slide before each measurement. Five microscopic fields were screened, 10 cells/field were selected and no less than 50 cells/tumor case were
assessed. Error bars show +/2 SD of mean and the P value was determined (** P,0.005 * P,0.001; Chi- square test). The data are representative of
four independent experiments performed in triplicates.
doi:10.1371/journal.pone.0011135.g002
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PAR1 and Etk/Bmx expression in malignant breast cancer
progression. PAR1-Etk/Bmx association was also demonstrated
by co-immunoprecipitation analysis of MDA-MB-435 cells
(expressing both endogenous PAR1 and Etk/Bmx) (Figure S3B).
Hierarchy of binding
Next, we wished to determine the chain of events mediating the
signaling of PAR1 C-tail-Shc and Etk/Bmx. To this end, analysis of
MCF7 cells that express little to no hPar1 were ectopically forced to
over-express hPar1. When co-immunoprecipitation with anti- PAR1
antibodies following PAR1 activation was performed, surprisingly,
no Shc was detected in the PAR1 immunocomplex (Fig. 6A;
MCF7/hPar1; right panel). Shc association with PAR1 was fully
rescued when MCF7 cells were initially co-transfected with Etk/
Bmx (Fig. 6A), with abundant assembly of Shc in the immunocom-
plex. Thus, Etk/Bmx is a critical component that binds to activated
PAR1 C-tail and enables subsequent binding of Shc. Shc may bind
either to phosphorylated Etk/Bmx, via the SH2 domain, or in an
unknown manner to the PAR1 C-tail, provided that Etk/Bmx is
present and is PAR1 -bound. One cannot, however, exclude the
possibility that Bmx binds first to Shc and only then does the
complex of Etk/Bmx-Shc bind to PAR-1.
Identification of PAR1-Etk/Bmx binding region: functional
consequences
Peptides (representing various regions in PAR1 C-tail) were used
in a competition analysis assay for the binding of PAR1 cell lysates
to GST-PH-Etk/Bmx. An 18-amino-acid peptide encompassing
residues 375–392 of PAR1 C-tail (e.g., termed peptide 4) yielded a
dose-dependent inhibition within the range of 1–1000 nM applied
peptide (Fig. 6B). Two other peptides, representing PAR1 C-tail
387–400 (Fig. 6Bii; termed peptide 5) or residues 393–412 (data
not shown), did not compete.
Based on the competition assay we prepared mutated hPar1
constructs with successive replacement of seven residues (378–384;
Figure 3. PAR1 C-tail recruits Shc adaptor protein. A. PAR1 GST-C-tail binds Shc adaptor. MDA-MB-435 cell lysates were applied to a GST- PAR1
C-tail or GST control column. After an adequate binding period of the designated cell lysates to the columns, a washing step was performed. This step
was performed in order to wash out all non-specific proteins, leaving the GST- PAR1 -C-tail column firmly bound to targeted cell lysate proteins. Next,
specifically-bound proteins were eluted via the addition of gel ‘‘sample buffer’’ and detected by western blot analysis using anti-Shc antibodies. B
and C. Co-immunoprecipitation analyses of PAR1 and Shc. Lysates of non-activated or TFLLRNPNDK-activated MDA-MB-435 cells were co-
immunoprecipitated with either anti- PAR1 (B) or anti-Shc (C) antibodies. D. PAR1 binds to Shc-SH2 domain. MDA-MB-435 cell lysates were loaded onto
columns of GST-Shc-SH2, GST linked to a tandem SH2 from a non-relevant protein, or GST alone. Specifically-bound proteins were eluted and
detected with anti- PAR1 antibodies. Ei. Schematic representation of PAR1 -C-tail. The scheme illustrates PAR1 structure. IL - internal ligand, TM -
transmembrane. Important tyrosine (Y) residues are indicated and the conserved sequence is gray. Serine residues in the C-tail region that may be
involved in PAR1 -Shc association are indicated in red. Eii. Analysis of PAR1 C-tail Y-residues by NetPhos 2.0 server.Y 381,Y 397 and Y420 were scored highly
likely to undergo phosphorylation, as shown in the table. ‘‘Pred’’ means ‘‘prediction’’ for the predicted score of each of the Y tyrosine residues thati s
relevant to phosphorylation.
doi:10.1371/journal.pone.0011135.g003
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HA-wt hPar1 showed the following outcome (characterization and
proper expression of the mutant is shown in Figure S4): HA-wt
following activation (Fig. 7A). We thus conclude that the critical
region for Etk/Bmx binding to PAR1 C-tail resides in the vicinity
of CQRYVYS.
Activated MCF7 hPar1-7A mutant cells (also expressing Etk/
Bmx) failed to invade Matrigel-coated membranes, as compared to
a potent invasion level obtained by activated wt hPar1 (Fig. 7B).
In a parallel experiment, a wound assay for the rate of cell
migration, showing the ability of the cells to fill in gaps in an
MDA-MB-435 cell monolayer, was performed. Rapid closure of
the hPar1, but not HA-hPar1-7A, exhibited binding association
with Etk/Bmx wound was observed following TFLLRNPNDK
PAR1 activation. This PAR1 -induced cell migration was markedly
inhibited when the cells were infected with siRNA-Etk/Bmx
construct to knock down the endogenous Etk/Bmx levels present
in MDA-MB-435 cells (Fig. 7C, top panel). Similar inhibition was
obtained in the presence of the PAR1 antagonist, SCH 79797
(Fig. 7C, bottom panel), pointing to the important role of both
PAR1 and Etk/Bmx in wound closure/migration of PAR1-
activated MDA-MB-435 cells. The highly ordered tissue organi-
zation of normal epithelia is aggressively disrupted in pathological
conditions. This is well recapitulated in the MCF10A cell-growth
model, mimicking epithelia apico-basal polarity (24). We exam-
ined the morphogenesis of MCF10A mammary acini in three-
dimensional (3-D) basement membrane cultures. Normal-appear-
ing intact spheroids are formed in the presence of control Etk/
Bmx-expressing MCF10A cells and activation by SFLLRNPNDK,
a PAR1 agonist peptide (Fig. 8A; a, b). In contrast, in the presence
of ectopically forced hPar1 (expressing also Etk/Bmx) and
following PAR1 activation, an oncogene-like, migratory morpho-
Figure 4. Y381A hPar1 construct enhances liver metastasis formation. A. MRI analysis. CT-26 mouse carcinoma cells (that do not express
endogenous hPar1), ectopically forced to express either wt hPar1 or Y381A hPar1 constructs, were injected intra-splenically into CB6F1 mice to
generate liver metastases. Tumor assessment was performed using T2W fast SE images (TR/TE=2000/40 ms). Representative axial liver sections of wt
hPar1 or Y381A hPar1 CT-26-transfected cells, obtained at day 16, in the absence (left panel) or presence (right panel) of SFLLRN, are seen. Liver
margins are marked with a dashed green line; yellow lines mark tumor foci; scale bar represents a size of 1 cm and applies to all the images in A. B.
Anatomical and histological examination. Gross anatomical photos (Top) and H&E staining of liver sections (harvested on day 16) of activated wt
hPar1or Y381A hPar1 CT-26 cells. T=tumor and N=normal; yellow lines mark tumor foci; original magnification 6100. C. Histogram of the number of
liver metastases per mouse as measured by MRI. The experiments were performed in the presence or absence of the PAR1 agonist peptide (n=3–
5 mice/group). Activation of PAR1 accelerated both tumor size and the number of detectable foci as well as their time of appearance. X stands for
sacrificed mice with overloaded liver tumors.
doi:10.1371/journal.pone.0011135.g004
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of the cell-cell tight junction contacts and the invaded basement
membrane architecture (Fig. 8A; c and g). Significantly, when the
MCF10A cells (in the presence of endogenously expressed Etk/
Bmx) were infected with the mutant cytoplasmic form of hPar1
(hPar1-7A) and SFLLRNPNDK PAR1 -activated, nearly normal-
appearing spheroid morphology was obtained (Fig. 8A; d, f). This
outcome highlights the fact that by preventing immobilization of
Etk/Bmx on PAR1 C-tail, inhibition of invasion and lack of apico-
basal polarity morphogenesis of an oncogene-like phenotype in
MCF10A cells are observed.
Discussion
In the present study we characterized the contribution of
PAR1 signaling events in breast cancer progression. We utilized
constructs of hPar1, including wt hPar1 and either deleted or
mutant hPar1 forms, and analyzed them for their ability to
induce tumor development in mouse mammary gland and
colorectal-liver metastasis models in vivo,a sw e l la sc h a r a c t e r -
izing them biochemically in vitro. Injection of cells expressing wt
hPar1 or Y397Z hPar1 into mouse mammary glands resulted in
pronounced mammary tumor growth and angiogenesis. The
Figure 5. Physical association between PAR1 and Etk/Bmx. A. PAR1 is physically associated with Etk-PH domain. Lysates of cells over-expressing
Y397Z, wt or truncated hPar1, andlysates of cells that do not express PAR1 (e.g., JAR) were applied to a GST-Etk-PH column. Noticeably,highly metastatic
MDA-435 cells express high levels of PAR1 Specifically-bound proteins were detected using anti- PAR1 antibodies. While Y397Z and wt hPar1 showed
specific PAR1 association, lysates of the truncated hPar1 or JAR cells showed no binding. B. Purified PAR1 C-tail. PAR1 C-tail was cleaved from the
immobilized GST-C-tail, purified and re-applied onto a GST-Etk-PH domain column. Specific binding is observed regardless of whether purified wt or
mutant cleaved C-tail is analyzed. No binding was observed when only GST beads were used. C. GST- PAR1 C-tail of wt and mutants. Lysates of HEK293
cells transfected with either Etk/Bmx (A–D) or kinase-inactive Etk/Bmx (KQ; E–G), applied on various GST-PAR1-C-tail columns (PAR1-C-tail of wt, Y381A,
Y383A) or GST-control column. The GST-C-tails from either wt hPar1 or mutants Y381A and Y383A are strongly associated with both wt (A–D) and kinase-
inactive (KQ; E–G) Etk/Bmx. Control-free GST did not show any binding of KQ Etk/Bmx (data not shown). Specifically-bound proteins were identified
using anti-Etk/Bmx antibodies. Levels of GST were used as a control for protein loading. D. Immunohistological staining of PAR1 and Etk/Bmx on breast
tissue biopsy specimens. Antibodies directed against PAR1 (upper panel) or Etk/Bmx (lower panel) were applied to normal and cancerous breast tissue
specimens. The cancerous tissues include DCIS (ductal carcinoma in situ), IDC (invasive ductal carcinoma) and lobular invasive carcinoma (lobular
carcinoma). The combined histological results were assessed and scored as outlined in the Materials and Methods section. The measurements per slide
section was carried out using anatomical compartments, using an ocular micrometer (WHIOX2, Olympus, New Jersey, USA). The microscope was
calibrated with a micrometer slide before each measurement. All measurements were performed on the monitor screen using a 640 objective. On
examining the sections for selection of fields tumorcellsfrom themost cellulararea at thecenter of the tumor were selected. Necroticandinflammatory
area were avoided. Eight microscopic fields were screened, 10 cells/field were selected and no less than 50 cells/tumor case were assessed. The positive
rate of staining is expressed as a mean 6 SD pertumor histological subtype from selectedcases. Specific staining is observed in both PAR1 andEtk/Bmx,
with particularly strong staining seen in IDC and lobular carcinoma. No staining is seen in the normal breast tissue. This staining represents total of3 6
cases as outlined for each histological subtype in the table below, performed three times per category.
doi:10.1371/journal.pone.0011135.g005
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mic tail, was incapable of promoting PAR1 -induced tumors in
vivo. These findings emphasize the pivotal role of the
cytoplasmic tail in PAR1 function. Antibody-array analyses for
the detection of signaling partners that bind to PAR1 revealed
the involvement of Shc and Etk/Bmx, among others. We
describe herein a novel signaling complex formed between Etk/
Bmx and Shc assembled onto the PAR1 C-tail, thus providing a
Table 1. Expression of PAR1 and Etk/Bmx in breast cancer biopsy specimens (representing Fig. 5D).
Histological
subtype
Cases
(N=36)
Positive cells
Mean ± SD +1 +2 +3
PAR1 Etk/Bmx PAR1 Etk/Bmx PAR1 Etk/Bmx PAR1 Etk/Bmx
Normal 12 0.860.2 1.260 . 2 0 10 00 0
DCIS 8 12.563.7 1463.0 2 (25%) 1 (12.5%) 6 (75%) 7 (87.5%) - -
IDC 9 40610.5 42612.3 2 (22%) 1 (11%) 1 (11%) 0 5 (55%) 6 (66%)
Lobular carcinoma 7 4567.3 43611.6 1 (14%) 0 1 (14%) 1 (14%) 6 (85%) 5 (71.4%)
Histological scoring of (N) cases: +1 less than 25% positive cells (weak positive); +2 between 25–75% positive cells (moderate); +3 more than 75% of positive cells
(strong). All controls were negative (0–5% positive cells). Extent of expression classified by score (1–3), number of positive cells/field (x=8).
doi:10.1371/journal.pone.0011135.t001
Figure 6. Hierarchy of Shc and Etk/Bmx binding and identification of binding region on PAR1 C-tail. A. Etk/Bmx is needed for Shc
association with PAR1 C-tail. MCF7 cells before (MCF7/hPar1) and after (MCF7/hPar1&Etk/Bmx) forced Etk/Bmx and hPar1 co-immunoprecipitation with
Shc. No Shc is immunoprecipitated with activated PAR1 when Etk/Bmx is absent (right panel: MCF7/hPar1; wt hPar1). In contrast, extensive co-
immunoprecipitation is seen in the presence of forced Etk/Bmx (MCF7/hPar1&Etk/Bmx). This is true regardless of the various constructs of hPar1
expressed: Y383A&Y381A hPar1, Y397Z hPar1, Y381A hPar1 or wt hPar1. The IP was performed using anti- PAR1 (ATAP, Santa Cruz, CA). B. Peptide
competition for PAR1 binding to GST-PH-Etk/Bmx. i. Peptide 4, encompassing residues 375–396 of PAR1 C-tail, competes with PAR1 for binding to the
GST-PH-Etk/Bmx. Specific binding of PAR1to the GST-PH-Etk/Bmx is inhibited in the presence of increased peptide concentration (200 nM-1 mM).
Lower panel: Representative histograms show the relative intensities of the bands expressed as a ratio of PAR1to GST-PH. Bii. Peptide 5, representing
another region (e.g., 379–402), does not compete at a concentration of 1 mM. GST protein serves as a loading control. Lower panel: Representative
histograms show the relative intensities of the bands expressed as a ratio of PAR1 to GST.
doi:10.1371/journal.pone.0011135.g006
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angiogenesis.
Studies of Par1-deficient mice revealed a critical role for PAR1
in blood vessel formation [13]. PAR1 induces tumor angiogenesis
via the up-regulation of at least VEGF and Gro oncogenes
(27,28). Furthermore, hPar1 gene withdrawal leads to the selective
regression of immature but not mature blood vessels [21]. We
show here that tumors generated by either wt hPar1 or persistent
Y397Z hPar1 are capable of inducing marked vascularization, as
compared to only a few blood vessels formed by the truncated
hPar1-induced tumors. Together, these results emphasize a
central role for PAR1 expression and signaling in tumor
progression.
A critical role for Etk/Bmx and Shc was demonstrated by their
selective recruitment to activated PAR1 C-tail. Moreover, the
prime event of Etk/Bmx binding is a prerequisite for further
PAR1-Shc association. We demonstrate herewith the hierarchy
and sequence of events during PAR1 signaling in breast cancer
progression. While PAR1-induced Shc phosphorylation has been
previously reported [14,22,23], we provide here the first evidence
for a physical association between Shc and PAR1. Substitution of
tyrosine residues in PAR1 C-tail by alanine did not abrogate the
recruitment of Shc to PAR1 tail, indicating that PAR1 tyrosine
residues are not involved in the direct association between PAR1
and Shc. Furthermore, the mutant Y381A showed enhanced
metastatic capabilities when compared to wt hPar1 in a colorectal-
Figure 7. Functional consequences of mutant hPar1-7A versus wt hPar1.A i. Schematic representation of wt hPar1 and the mutant hPar1-7A.
Aii. The ectopic expression of hPar1-7A mutant construct abrogates binding of Etk/Bmx to PAR1 C-tail. Stable clones of either HA-tagged wt hPar1 and/or
a mutant construct of HA-hPar1-7A were activated and further analyzed for co-immunoprecipitation of PAR1 with Etk/Bmx. The IP was carried out
using anti-HA (sc-7392; Santa Cruz, CA). The blots were detected by anti-Bmx (Transduction Laboratories, BD Biosciences, CA) for the identificationo f
Etk/Bmx-associated PAR1. Levels of the HA-tag (for PAR1) are shown in the middle panel. Similarly, levels of PAR1 are also shown by application of
anti- PAR1 (ATAP; Santa Cruz, CA) (lower panel). The right section shows levels of plasmid transfection efficiencies in the cells, as indicated by HA-
PAR1 and Etk/Bmx analysis by western blots. As seen, only the wt hPar1 co-immunoprecipitated with Etk/Bmx (wt hPar1), while the mutant HA-hPar1-
7A clone (mutant clone hPar1- 7A) failed to co-immunoprecipitate. This takes place under conditions whereby both constructs are well expressed, as
evidenced by anti-HA-antibodies (western blot; right panel). B. Matrigel invasion assay of either MCF7 cells stably expressing HA-wt-hPar1and Etk/Bmx,
or HA-hPar1-7A mutant and Etk/Bmx. Invading cells were counted and the mean 6 SD of ten fields per filter was determined. Stable HA wt hPar1 clone
or HA-hPar1-7A mutant clone were co-transfected with Etk/Bmx construct and TFLLRNPNDK-activated. Marked Matrigel invasion is seen in the wt
hPar1 and Etk/Bmx clones. Low invasion levels are observed in the presence of hPar1-7A mutant and Etk/Bmx, hPar1 alone, empty vector, vector and
Etk/Bmx or PAR1 antagonist. These data are representative of three experiments. Ci. Migration assay for wounding-scratch monolayer cells. MDA-MB-
435 cell monolayer (expressing endogenous Etk/Bmx) were scratched to introduce an equal gap-area under the following conditions: control
untreated cells, TFLLRNPNDK-activated or SiRNA-Etk/Bmx and TFLLRNPNDK-activated. In this set, rapid closure of the wound was obtained 24 hours
under PAR1 activation as compared to control untreated cells. In contrast, no migration and closure of the wound was seen when the Etk/Bmx level of
the cells were knocked down and they were TFLLRNPNDK-activated. In another set of wound introduction experiments, attenuated wound closure
was seen in the presence of the V antagonist SCH79797 and SFLLR NPNDK PAR1 activation for 24 h, similar to the control untreated cells. These data
are representative of four experiments. Cii. RT-PCR analysis showing the level of Etk/Bmx in MDA-MB-435 cells before and after SiRNA- Etk/Bmx cell
infection.
doi:10.1371/journal.pone.0011135.g007
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substitution (Y381A) most likely endows PAR1 with better
accessibility to essential signaling proteins and thereby enables
enhanced metastasis (a hypothesis that is currently under
investigation). The fact that the tyrosine residues in PAR1 C-tail
do not play a role in the binding of Shc implies the requirement of
a third mediating partner. Indeed, Etk/Bmx binding to PAR1 C-
tail through the PH-domain is required for PAR1 -Shc association.
One cannot, however, exclude the possibility that Bmx binds first
to Shc and only then does the complex of Etk/Bmx-Shc bind to
PAR1.
The fact that we have obtained tumors in vivo following
implantation of either MCF7 cells over-expressing wt hPar1, or
Y397Z hPar1 in the mammary fat pads of mice (Fig. 1), raises the
issue as to the significance of Etk/Bmx in vivo. When we have
immunostained for Etk/Bmx, xenograft sections derived from the
tumors obtained of MCF7 cells over-expressing these constructs,
abundant and high levels of Etk/Bmx was found in tumors
generated by MCF7/wt hPar1 and MCF7/Y397Z hPar1. In-
contrast, no Etk/Bmx was seen in either MCF7/empty vector or
MCF7/truncated hPar1 small tumors (see Figure S5). This finding
recapitulates the presence of Etk/Bmx in tumors generated by
MCF7 cells over-expressing hPar1, in vivo in a manner that remains
to be fully explored. One attractive possibility is that environ-
mental cues in-vivo are responsible for the expression of Etk/Bmx
in PAR1-derived tumors. It is plausible that the very low
endogenous levels of Etk/Bmx originally present in MCF7 cells
are markedly induced in vivo, due to micro environmental signals
(in a yet unknown manner).
The recruitment of Etk/Bmx and Shc to PAR1 C-tail provides a
bridge linking PAR1 with receptor tyrosine kinases (RTKs) and
associated downstream signaling pathways. For example, the
proto-oncogene Src plays a pivotal role in integrin activation
during tumor progression [24]. While the C-terminal Src kinase
consists of SH3, SH2 and kinase domains, it may be recruited to a
phosphorylated site in Etk/Bmx (following PAR1 activation; see
Figure 8. Morphogenesis of MCF10A spheroids infected with either wt hPar1, mutant hPar1-7A or with Etk/Bmx maintained in 3-D
Matrigel cultures. A. Upper panel. Representative phase-contrast microscopic images of MCF10A cells under the following conditions: a. control
untreated MCF10A. b. MCF10A cells infected with Etk/Bmx and SFLLRNPNDK PAR1 -activated. c. MCF10A cells infected with both wt hPar1 and Etk/
Bmx and SFLLRNPNDK-activated. d. MCF10A cells infected with both mutant hPar1-7A and Etk/Bmx and SFLLRNPNDK-activated. Lower panel.
Representative confocal microscopic images of MCF10A acini. e. Control untreated MCF10A, DAPI stained nuclei in a representative spheroid. f.
MCF10A cells infected with both the mutant hPar1-7A and Etk/Bmx and SFLLRNPNDK-activated; DAPI staining of spheroid nuclei. g. MCF10A cells
infected with both the wt hPar1 and Etk/Bmx and SFLLRNPNDK-activated; DAPI staining of the nuclei. h. MCF10A cells infected with both the mutant
hPar1-7A and Etk/Bmx and SFLLRNPNDK-activated, stained for cell-cell contact with anti-E-cadherin. B. Schematic representation of MCF10A spheroid
development in 3-D Matrigel cultures. C. RT-PCR analyses for the different MCF10A-infected cells. Levels of expression as compared to those of a
house-keeping gene (GAPDH). A. MCF10A-infected wt hPar1 B. MCF10A infected with mutant hPar1-7A. C. Empty vector infected-MCF10A cells. D.
Control, untreated MCF10A cells. E. MCF10A cells infected with Etk/Bmx.
doi:10.1371/journal.pone.0011135.g008
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Etk/Bmx-Shc and Src complex formation remains to be fully
elucidated.
Whereas Etk has been shown to mediate integrin signaling by
binding to the FAK FERM domain through the Etk PH domain
[25], activation of PAR1 has also been shown to induce FAK
phosphorylation and integrin signaling via cross talk with avb5
integrin [26]. However, it is not known how PAR1 activation leads
to avb5 integrin activation and FAK phosphorylation. While, in
breast cancer, activated PAR1 is engaged in binding Etk/Bmx via
the PH domain, thus occupying this site, it is plausible that the
Pro-712/713 proline-rich region of FAK (e.g., Pro-X-X-Pro-X-
Arg) associates with the SH3 domain present in Etk/Bmx,
connecting PAR1 to integrins via FAK association to Etk/Bmx.
This possibility needs to be fully explored. It has also been
demonstrated that the docking protein p130Cas forms a complex
with Etk/Bmx. This protein plays a role in the formation of focal
adhesion complex sites, the regulation of actin cytoskeleton
reorganization and cell migration. Since Cas undergoes tyrosine
phosphorylation prior to complex formation, it is feasible that
phosphorylated p130Cas associates with the SH2 domain of PAR1
-C-tail immobilized Etk/Bmx [27].
PAR1 induces activation of the small GTPase RhoA, which
participates in formation of focal adhesions and in regulating the
reorganization of the actin cytoskeleton. It was suggested that Etk/
Bmx activates Rho A by releasing the GDI from the inactive
RhoA-GDI complex through the interaction with Etk/Bmx PH
domain [28]. Perhaps a balance is obtained between the free Etk/
Bmx-PH domain in activating RhoA and the PAR1-C-tail
immobilized Etk/Bmx-PH domain, in the delicate control of
cytokeletal reorganization and actin stress fiber formation during
breast cancer progression.
Akt/PKB, first identified as the cellular homologue of the
transforming oncogene v-Akt [29], is a core component of the
phosphoinositide 3-kinase (PI3K) signaling pathway and effectively
promotes cancer cell survival and proliferation. Activation of PI3K
may be mediated via association of the SH2 domain in one of the
two (85 kDa and 110 kDa) PI3K domains (most likely p85) with
phosphorylated tyrosine residues in Etk/Bmx, following PAR1
activation. This leads to the recruitment of PI3K to the cell
membrane and ultimately to activation of the serine/threonine
kinase Akt, an immediate downstream target acting to promote
breast cancer survival.
Shc in the complex (PAR1 -Etk/Bmx-Shc) may recruit the Grb2
(growth factor-bound protein-2)-SOS (Son of sevenless) complex to
the membrane via binding of the SH2 domain of Grb2 to the
phosphotyrosine on Shc. SOS, a GEF for Ras, can then exchange
the GDP bound to Ras GTP. Once Ras binds GTP, it is then
activated, leading to the ERK activation cascade.
Increasing evidence suggests that the Btk kinase family plays a
central role in various cellular processes [18]. Recently, Bmx
transgenic mice were demonstrated to exhibit skin hyperplasia,
inflammatory cell recruitment and strong dermal angiogenesis,
as well as accelerated wound healing [30]. In agreement with
these transgenic animal characteristics, Etk/Bmx was shown to
interact physically with a vast number of proteins, among them
FAK [25], Src [31], G-proteins [32,33,34], STAT3[19] and
P21[35]. We found that Etk/Bmx kinase is phosphorylated
following PAR1 activation (see Fig. 3A), suggesting that kinase
activation is important for the downstream signaling of PAR1.A
seven-amino-acid sequence region in the PAR1 C-tail portion
was identified as the site required for association with the Etk/
Bmx-PH domain. Part of this region, located in the 8
th helix
region, as revealed by the X-ray structure of rhodopsin, was
previously reported to be significant for platelet PAR1 activation
[36].
PAR1 C-tail is a highly conserved region among species,
implying the importance of this region in protein-protein interaction
and signaling. Stable MCF7 clones expressing both wt hPar1 and
Etk/Bmx exhibit enhanced invasion properties potently inhibited
by a PAR1 -specific antagonist. In contrast, low levels of invasion
are shown by stable MCF7 clones of Etk/Bmx and hPar1-7A
mutants. Similar data, further supporting the importance of Etk/
Bmx in PAR1 -induced migration, is demonstrated by wound-gap
closure in cell monolayers. The key role of Etk/Bmx is also shown
in the nearly normal acinar structure of MCF10A cell cultures
maintained in a three-dimensional (3-D) environment in vitro. This
3-D cell culture mimics large, epithelial tissues in vivo, in the
context of apico-basal polarized structure. The ectopic forcing of
wt hPar1 in MCF10A cells, followed by activation, results in
dramatic altered structures of disrupted tight-junction contacts,
complete loss of cell polarity and extensive protrusions of invaded
basement membranes. Blocking Etk/Bmx binding to PAR1 by
over-expressing hPar1-7A mutant in MCF10A cells maintained in
3-D basement membrane cultures abrogates the oncogene-like
phenotype. Instead, nearly ball-shaped spheroids of apico-basal
polarization are obtained. This outcome strongly supports a
fundamental role for Etk/Bmx in PAR1 -induced invasion. Our
data contribute to a list of Etk/Bmx counter-partners, such as
TNF, that mediate angiogenesis via binding to a 16-amino-acid
sequence of TNFR2, which binds to multiple Etk/Bmx binding
domains (PH, TEC and SH2) [37]. Similarly, the Etk-PH-domain
has been shown to regulate integrin signaling, and promote cell
migration through the specific association of FAK via the FERM
domain [25]. In addition, Etk/Bmx immobilized to PAR1 C-tail
may provide a central junction site for possible cross-talk between
PAR1 and EGFR, as well as ErbB2/HER2, following PAR1
activation [38].
Our study identifies essential signaling partners in PAR1 -
mediated breast cancer progression, determines the hierarchy of
binding and identifies a critical associating region in the PAR1 C-
tail. This is the first demonstration of the PAR1 C-terminus serving
as a scaffold tail. The identification of a PAR1 C-tail binding
domain may provide a platform for new therapeutic vehicles in the
treatment of breast cancer.
Materials and Methods
Cell culture
MCF7 and MDA-MB-435 human breast carcinoma, CT-26
mouse colon carcinoma, HEK-293 cells and the African green
monkey kidney fibroblast cell line COS1 (these cell lines were
obtained from the ATCC, VA, USA) were maintained in DMEM
with 10% fetal calf serum. Stable clonal cell lines over-expressing
wt hPar1, Y397Z hPar1, truncated hPar1 and Y/A mutants;
Y381A&383A hPar1or the wt-Etk and Etk-KQ were selected for
G418 resistance (800 mg/ml).
Plasmids and transfection
MCF7 cells were transfected with 1–2 mg of either wt human
hPar1 or truncated hPar1 or Y397Z hPar1 cDNA, or with a control
pcDNA3 vector (Invitrogen, Carlsbad, CA) using FuGene
transfection reagent (Roche Molecular Biochemicals, Indianapolis,
IN). Transfected cells were selected with G418 (800 mg/ml) to
obtain stable populations of cells expressing hPar1 and the variants.
Etk/Bmx plasmids (e.g., wt, kinase-dead, KQ and GST-PH-Etk/
Bmx) [18,19] were transfected into HEK-293 cells using the same
protocol as previously described.
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RNA was isolated with Tri-Reagent (MRC, Cincinnati, OH)
according to the manufacturer’s instructions. After reverse
transcription of 1 mg total RNA by oligo (dT) priming, cDNA
was amplified using Taq DNA polymerase (Promega, Madison,
WI). Comparative semi-quantitative PCR was performed using
the following primers: GAPDH sense: 5’-CCA CCC ATG GCA
AAT TCC ATG GC-3’ and antisense: 5’-TCT AGA CGG CAG
GTC AGG TCC ACC-3’ primers. PAR1 N-terminus primers
were as follows: hPar1-sense: 59- CTCGTCCTCAAGGAG-
CAAAC-39, antisense orientation: 59-TGGGATCGGAACTT-
TCTTTG-3’.
(resulting with a 564-bp PCR product). PAR1 C-tail primers -
sense: 59-TAC TAT TAC GCT GGA TCC TCT GAG-39 and
antisense: 59-CTT GAA TTC CTA AGT TAA CAGCTT-39.
These primers give rise to a 181-bp product corresponding to the
entire PAR1 C-tail site, as follows:
YY - YASSECQRYVYSILCCKESSDPSYNSSGQLMASK-
MDTCSSNLNNSIYKKLLT.
Animal studies: Mammary gland model
Female athymic nude mice at 6–8 weeks of age were pre-
implanted subcutaneously with pellets containing 1.7 mg b-
estradiol(60-dayrelease,Innovative ResearchofAmerica,Sarasota,
FL). Mouse mammary pads were then injected with 1610
7 MCF-7
cells stably transfected with hPar1 wt and mutant constructs (e.g., wt,
Y397Z and truncated) or pcDNA3 control plasmid. Mice were
monitored for tumor size by external caliber measurements (length
and width) on days 10, 22, 25, 29, 33, 36 and 45. Tumor volume (V)
was calculated by V=L6W260.5, where L is length and W is
width. On day 45, mice were sacrificed and tumors were removed,
weighed and fixed in formalin for histology. All animal experiments
were approved by the animal committee of the Hebrew University,
Jerusalem, Israel (MD-107.05-4).
Liver metastasis model
CT-26 mouse colon carcinoma cells were stably transfected with
either wt hPar1 or hPar1-Y381A constructs. The activation of PAR1
(using the peptide SFLLRN) was performed prior to injection into
the mice. CB6F1 mice were anesthetized (75 mg/kg ketamine
+3 mg/kgxylazine,i.p.),andthespleenwasexteriorizedthroughan
incision (1.0 cm) on the left side of the mouse. CT-26 cells
(10
4 cells/mouse) transfected with the different constructs (e.g.,
hPar1, hPar1 Y381A, mock-transfected vector) were injected into the
spleen using a 30-gauge needle. The cell suspension was allowed to
enter the portal circulation over a short period (5 minutes), after
which the spleen was removed, as previously described [39]. The
wound was sutured and the animal was allowed to recover. MRI
images were monitored every 2–3 days on a 4.7T Bruker Biospec
spectrometerusinga bird-cagecoil.Tumorassessment was made by
serial coronal and axial T2W fast SE images (TR/TE=2000/
40 ms). All experiments were performed in accordance with the
guidelines of the Animal Care and Use Committee of the Hebrew
University, Jerusalem, Israel (MD-107.05-4).
PAR1 activation
PAR1 was activated by the SFLLRN (H-Ser-Phe-Leu-Leu-Arg-
Asn-NH2) peptide, the TFLLRNPNDK peptide, a selective PAR1
agonist, or thrombin (1 U/ml).
Histology
Tissue samples derived from the primary tumors were fixed with
4% formaldehyde in PBS, embedded in paraffin and sectioned (5-
mm sections). After de-paraffinization and re hydration, sections
were stained with hematoxylin and eosin (H&E) or subjected to
immunohistochemistry using specific antibodies.
Histological evaluation and scoring
The combined histological results were assessed and scored as
previously described[40,41]. The measurements per slide section
was carried out using anatomical compartments, using an ocular
micrometer (WHIOX2, Olympus, New Jersey, USA). Slides
review was independently performed by two investigators (BM
and RB). Discrepancies were resolved by simultaneous re-
examination of the slides by both investigators using a double-
headed microscope. The microscope was calibrated with a
micrometer slide before each measurement. All measurements
were performed on the monitor screen using a 640 objective. On
examining the sections for selection of fields tumor cells from the
most cellular area at the center of the tumor were selected.
Necrotic and inflammatory area were avoided. Eight microscopic
fields were screened, 10 cells/field were selected and no less than
50 cells/tumor case were assessed. The positive rate of staining is
expressed as a mean 6 SD per tumor histological subtype from
selected cases.
Immunohistochemistry
Sections were subjected to inactivation of endogenous perox-
idase (3% H2O2 in DDW), antigen retrieval by microwave oven
(3 min) in citrate buffer (0.01 M, pH 6.0), and blocking with 10%
goat serum in PBS. Sections were then incubated with antibodies
directed against Von-Willebrand factor (anti-factor VIII, DAKO,
Carpinteria, CA), Ki-67 (Clone SP6, Lab Vision-NeoMarkers,
Fremont, CA), or an endothelial cell-specific lectin (Bandeiraea
simplicifolia BS-1 isolation) [42], followed by incubation with
horseradish peroxidase-conjugated anti-rabbit antibody (DAKO,
Carpinteria, CA). Color was developed by incubation (10 min)
with the Zymed AEC substrate kit (Zymed Laboratories,
South San Francisco, CA), and counterstained with Mayer’s
hematoxylin.
Preparation of hPar1 constructs: truncated hPar1, Y397Z
hPar1, Y381A hPar1 and Y383A hPar1
Detection of hPar1 was carried out using primers: sense
orientation: 59- CTCGTCCTCAAGGAGCAAAC-39, antisense
orientation: 59-TGGGATCGGAACTTTCTTTG-3’. For the
PAR1 -C-tail primers: sense orientation: 59 -TACTATTAC-
GCTGGATCCTCTGAG-39, antisense: 59- CTTGAATTCC-
TAAGTTAACAGCTT-39. These primers give rise to a 181-bp
product corresponding to the entire PAR1 C-tail site, as follows:
YY - YASSECQRYVYSILCCKESSDPSYNSSGQLMASK-
MDTCSSNLNNSIYKKLLT
Using polymerase chain reaction, we constructed a PAR-1
mutant protein truncated in its cytoplasmic tail after amino acid
leucine 369 or at tyrosine 397. Truncated hPar1 at residue 369 was
designed as described in [14]. Y397Z construct: PAR-1 cDNA
served as a template for amplifying the fragment containing STOP
codon using the followed primers: sense: 5’-ATA AGC ATT GAC
CGG TTT CTG-3’ and antisense: 5’-GCT CTA GAT TTT
AAC TGC TGG GAT CGG AAC-3’. Replacement of tyrosine
residues at PAR1 cytoplasmic tail was achieved using specific
primers containing the point mutation. Primer sequences were as
follows: 381-sense: 5’-TGC CAG AGG GCT GTC TAC AGT
ATC TTA TGC-3’, 381-antisense: 5’- GAT ACT GTA GAC
AGC CCT CTG GCA CTC AGA-3’, 383-sense: 5’-GCC AGA
GGT ACG TCG CAA GTA TCT TAT GCT GCA AA-3’, 383-
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TCA G-3’. The amplified DNA fragment was digested with XbaI
and HindIII from PAR1 cDNA and cloned into a pcDNA3
plasmid, followed by DNA sequencing. To confirm the functional
integrity of the DNA constructs, wt and mutant cDNAs were
transiently expressed in COS-1 cells that were subsequently
subjected to FACS analysis with a PAR-1-specific antibody
(WEDE15-PE, Immunotech, Cedex, France).
HA-tag wt hPar1 and HA-mutant hPar1-7A C-tail
constructs
The mutants were designed for insertion of A at the carboxy
terminus of PAR1 residues 378–384: SSECQRYVYSILCCKESS
to SSEAAAAAAAILCC (named hPar1-7A mutant). For HA-tag wt
hPar1 construct PCR primers were designed and added down-
stream to the ATG start codon. Primers for the HA-tag are as
follows: sense: 5’- TAC CCA TAC GAT GTT CCA GAT TAC
GCT-3’ and anti-sense: 59-AGC GTA ATC TGG AAC ATC TA
TGG GTA-39. Replacement of seven residues with Ala (A) at
positions 378–384 was made by synthesis of oligos containing the
mutation. Primer sequences were as follows: hPar1 7A mutant:
sense: 5’- TCT GAG GCT GCT GCT GCT GCT GCA GCT
ATC TTA -3’ and anti-sens:e 5’- TAA GAT AGC TGC AGC
AGC AGC AGC AGC CTC AGA -3’. PCR products were then
used as primers on an hPar1 cDNA template to create an extended
product of introduced mutations into the full-length sequence. The
amplified DNA fragment was digested with PinAI and XbaI from
PAR1 cDNA and cloned into pcDNA3-hPar1 plasmid followed by
DNA sequencing.
GST-C-tail cloning
GST-C-tail of PAR1 fragment, containing 54 amino acids from
serine 369 to residue 425, was prepared using RT-PCR (59-TAC
TAT TAC GCT GGA TCC TCT GAG-39 and 59-CTG AAT
TCC TAA GTT AAC AGC TT-39). The resulting DNA fragment
was further cut with the appropriate restriction enzymes (BamH1
and EcoR1) and ligated into pGEX2T vector. The GST-C-tail was
separated by SDS-PAGE, which indicated that the fusion protein
of the C-tail was adequately prepared. The molecular weight of
GST protein is 27 kD and the GST-C tail fusion protein is 32 kD.
GST-Shc-SH2 and tandem SH2 were kindly provided by S.
Katzav, Hubert H. Humphrey Center for Experimental Medicine
and Cancer Research, Hebrew University-Hadassah Medical
School, Jerusalem.
GST fusion protein columns
Fusion proteins were purified from transformed Escherichia coli
bacteria that had been stimulated with isopropyl-b-D-thio-
galactopyranoside (IPTG) at a concentration of 0.3 mM. Bacteria
were lysed according to published procedures, and then
immobilized on glutathione Sepharose beads (Pharmacia). Briefly,
MDA-MB-435 cell lysates were applied to GST- PAR1 C-tail or
GST control columns. After 2 h binding periods to the designated
protein/s cell lysates to the columns, a washing step was
performed. The washes (63) were carried out using a ‘‘wash
buffer’’ including: 100 mM NaCL, 20 mM EDTA, 10 mM Tris,
pH 8.0 and 1% Triton x100. This step was performed in order to
wash out all non-specific proteins, leaving the GST- PAR1 -C-tail
column firmly bound to targeted cell lysate proteins. Next, elution
of bound proteins was performed via the addition of gel ‘‘sample
buffer’’ and appropriate boiling. The samples were run electro-
phoretically on SDS-PAGE gels, followed by immunoblotting with
the indicated antibodies and ECL detection.
GST-PH-Etk/Bmx
The PH domain in Etk/Bmx was bound to GST column as
previously described[25].
Purification of PAR1 C-tail fragments
PAR1 C-tail fragments were generated using a ‘‘thrombin
cleavage capture kit’’ (Novagen, Madison, WI; Cat no. 69022-3).
The enzyme used for the cleavage was biotinylated human
thrombin. Briefly, the cleavage was performed according to the
manufacturer instructions. Biotinylated thrombin was removed
from the cleavage reaction using streptavidin agarose beads, and
the cleaved peptides (e.g., wt PAR1 -C-tail and Y381A C-tail) were
isolated and loaded on a GST-Etk-PH column. After incubation
for 4 h the purified fragments were applied onto the GST-PH-
Etk/Bmx column and detected following gel separation and
western blotting analysis using anti- PAR1 antibodies (ATAP,
Santa Cruz, CA).
Flow Cytometry Analysis
To activate PAR1, thrombin (1 U/ml was added for 5 min. The
cells were detached from the plates with 0.5 mM EDTA in 0.1 M
sodium phosphate at pH 7.4 (Biological Industries), washed and
re-suspended in PBS. The cells were analyzed by FACS after
incubation for 60 min at 4uC with 10 mg/ml anti- PAR1 -wede-PE
antibodies.
Western blot and immunoprecipitation analysis
Cells were activated with agonist peptide TFLLRNPNDK for
the indicated periods of time and solubilized in lysis buffer
containing10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% TritonX-100, and protease inhibitors (5 mg/ml
aprotinin, 1 mM phenylmethylsulfonylfluoride, and 10 mg/ml
leupeptin) at 4uC for 30 min. The cell lysates were subjected to
centrifugation at 12,000 rpm at 4uC for 20 min. We used 400 mg
of the supernatants with anti- PAR1 (ATAP, Santa Cruz, CA
1 mg), anti-HA (anti-HA sc-7392; Santa Cruz, CA), anti-Shc or
Etk/Bmx antibodies (10 mg/ml). After overnight incubation,
Protein A-Sepharose beads (Amersham Pharmacia Biotech,
Buckinghamshire, UK) were added to the suspension (50 ml),
which was rotated at 4uC for 1 h. The immunocomplexes were
eluted and run electrophoretically on a 10% SDS-PAGE gel,
followed by transfer to an Immobilon-P membrane (Millipore).
Membranes were blocked and probed with 1 mg/ml amounts of
the appropriate antibodies as follows: anti- PAR1 thrombin
receptor mAb, (ATAP, from Santa Cruz, 1:1000); anti-Shc (BD,
1:2000); anti-Bmx (Transduction Laboratories, 1:1000) or anti-PY
(Upstate 4G10, 1:2500), suspended in 3% BSA in 10 mM Tris-
HCl, pH 7.5, 100 mM NaCl, and 0.5% Tween-20. After washes
the blots were incubated with secondary antibodies conjugated to
horseradish-peroxidase. Immunoreactive bands were detected by
enhanced chemiluminescence (ECL). Membranes were stripped
and incubated with anti-IP antibodies to ensure equal protein
load.
Anti- PAR1 polyclonal antibodies were generated using two
regions of the N-terminus portion R/SFFLRN by the synthetic
peptides NH2-CLLRNPNDKYEPFWED-COOH and NH2-K
SSPLQKQLPAFISC-COOH.
Antibody array
A custom-made antibody array (hypromatrix) containing thirty
antibodies against suspected proteins was prepared (see Fig. S2).
The antibodies were immobilized on a membrane, each at a pre-
determined position, and they retained their capabilities of
PAR1-Etk/Bmx in Breast Cancer
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proteins. MDA-MB-435 cells were activated for 10 min with
thrombin (1 U/ml). Untreated or activated cells were lysed with
Triton extraction solution: 15 mM Tris, pH 7.5, 120 mM NaCl,
25 mM KCl, 2 mM EGTA, 2 mM EDTA, 0.1 mM DTT, 0.5%
Triton X-100, 10 mg/ml leupeptin and 0.5 mM PMSF. Protein
extract was incubated on pre-blocked membrane for 2 h at room
temperature. The antibody array was washed with TBST and
incubated with biotinylated PAR1 antibody (ATAP) for 2 h at
room temperature. The antibody array was washed again with
TBST, and the membrane was incubated with HRP-conjugated
streptavidin for 1 h. Protein-protein interactions were detected by
ECL and exposure to X-ray film.
Matrigel invasion assay
Blind-well chemotaxis chambers with 13-mm diameter filters
were used for this assay. Polyvinylpyrrolidone-free polycarbonate
filters, 8 mm pore size (Costar Scientific Co., Cambridge, MA),
were coated with basement membrane Matrigel (25 mg/filter), as
previously described [43]. Briefly, the Matrigel was diluted to the
desired final concentration with cold distilled water, applied to the
filters, and dried under a hood. Cells (2610
5) suspended in
DMEM containing 0.1% bovine serum albumin were added to the
upper chamber. Conditioned medium of 3T3 fibroblasts was
applied as a chemo-attractant and placed in the lower compart-
ment of the Boyden chamber. Cells were incubated for 18 h on
filters at 37uCi n5 %C O 2. At the end of the incubation, cells on
the upper surface of the filter were removed by wiping with a
cotton swab. The filters were fixed and stained with DifQuick
System (Dade Behring Inc., Newark, NJ). Ten fields were chosen
from the lower surface of the filter and cells within each field were
counted. The mean +/2 SD of the ten fields was calculated for
each filter. Each assay was performed in triplicate.
MCF10A morphogenesis assay
The assay was performed as previously described (24). In brief,
while the MCF10A cells were maintained in DMEM/F12
medium with 20% donor horse serum, the cells for spheroid
assay (DMEM/F12 supplemented with 2% donor horse serum,
10 mg/ml insulin, 1 ng/ml cholera-toxin, 100 mg/ml hydrocorti-
sone, 50 U/ml penicillin and 50 mg/ml streptomycin) were
resuspended at a concentration of 10
5 cells per 4.0 ml. Eight-
chambered RS glass slides (Nalgene) were coated with 35 ml
Matrigel per well and left to solidify for 15 min. The cells were
mixed 1:1 with assay medium containing 4% Matrigel and 10 ng/
ml EGF, and 400 ml were added to each chamber of the Matrigel-
coated eight-chambered slide. Assay medium containing
SFLLRNPNDK PAR1 activation peptide and 5 ng/ml EGF was
replaced every 4 days. The images were taken between days 8–12.
In the representative experiment shown images were taken on day
10. The media and supplements were replaced every 4 days and
thus, the activating peptide was added fresh to the medium every 4
days.
Supporting Information
Figure S1 Surface expression of various hPar1 constructs (e.g.,
deletion constructs and Y/A mutations) following ectopic insertion
to MCF7 cells. A. PAR1 constructs (e.g., wt, deleted constructs
and Y/A mutations). Schematic representation of hPar1 deletion
constructs derived from human PAR1 cDNA. Mutations of Y/A
insertions of the functional relevant Y residues in PAR1 C-tail
(e.g., Y381A hPar1 and the double mutant Y381A&Y 383A hPar1)
whereby replacement of Y/A at positions 381 and 383 of PAR1 C-
tail was performed. B. FACS (fluorescent activated cell sorter)
analysis. Flow cytometric analysis of surface-expressed wt hPar1,
hPar1 deletion constructs, Y381A hPar1 and the double mutant
Y381A&Y 383A hPar1. Constructs were transiently expressed in
COS-1 cells and surface expression was determined by flow
cytometry analysis using anti-PAR1 abs (WEDE-PE 2584,
Immunotech), directed to detect cell surface levels of PAR1
(analyses performed on intact cells). Empty peak - represents the
isotype control antibody alone; black peak - represents PAR1
antibody. C. Histograms representing the surface expression of wt,
deleted and mutant hPar1 constructs before and after activation.
Surface expression levels of the various hPar1 constructs (e.g., wt
hPar1, truncated hPar1, Y397Z hPar1,Y 381A hPar1 and Y381A&
Y383A hPar1) transfected into COS-1 cells were determined. The
various COS-1 transfected cells were evaluated by FACS analysis
before (open bars) and after (black bars) a 30-minute activation
with thrombin. Similar results were obtained in MCF7 cells
expressing the hPar1 various constructs (data not shown). D. PAR1
expression levels in MCF7 cells transfected with various hPar1
constructs. Western blot analysis of MCF7 cells expressing either
empty vector (A) or Y397Z hPar1 (B), truncated hPar1 (C), the
double mutant Y381A&Y 383A hPar1(D), Y381A hPar1 (E), as also
wt hPar1 (F). Levels of protein loading were evaluated by b-actin.
Found at: doi:10.1371/journal.pone.0011135.s001 (4.60 MB TIF)
Figure S2 Antibody-array of protein-protein interactions and
physical association between PAR1 and the signaling partner Etk/
Bmx. A. Custom-made antibody array. Table lists antibodies
embedded on membranes showing the orientation map to create
the custom array, as described in Materials and Methods. B.
Lysates of MDA-435 cells before (i) and after (ii)thrombin (1 U/
ml, 15 min) activation were applied to the membranes. Specific
PAR-1 binding to the array was detected via incubation with
biotinylated anti-PAR1 antibodies.
Found at: doi:10.1371/journal.pone.0011135.s002 (4.60 MB TIF)
Figure S3 The phosphorylation status of Etk/Bmx associated
PAR1 following PAR1 activation. Ai. HEK-293 cells were
transfected with either wt Etk/Bmx or inactive KQ kinase -Etk/
Bmx. Lysates were immunoprecipitated with anti Bmx and
western blotted with 4G10 abs to detect levels of phosphorylation.
Western blot analysis shows the levels of either endogenous Etk/
Bmx (lanes c & d) or ectopically enforced Etk/Bmx (a & b) as
compared to a house keeping gene b-actin. Aii. Endogenous levels
of Etk/Bmx in HEK-293 cells. Western blot analysis was
performed in lysates of HEK-293 cells before (c,d) and after (a,b)
transfection with Etk/Bmx constructs. The equal loading levels
were determined by a house keeping b-actin protein levels. B.
PAR1-Bmx association. MDA-435 cells were TFLLRNPNDK-
activated. Lysates were co-immunoprecipitated with anti-PAR1
antibodies, and eluted proteins were detected with Bmx antibod-
ies. A strong association between PAR1 and Etk/Bmx was
observed as early as 1 minute after activation reaching maximal
levels after 10 minutes.
Found at: doi:10.1371/journal.pone.0011135.s003 (2.05 MB TIF)
Figure S4 Characterization of MCF7 clones of HA-tagged wt
and mutants of hPar1 constructs. A. FACS analysis of MCF7
clones. Surface expression of HA-wt hPar1 and HA-hPar1-7A, was
determined by using anti-PAR1 abs (WEDE-PE 2584, Immuno-
tech). Empty peak - represents the isotype control antibody alone;
black peak - represents PAR1 antibody. B. Histogram representing
surface levels of the constructs (e.g., HA-wt hPar1 and HA-hPar1
7A) as determined by FACS analysis. C. Western blot analysis of
MCF7 cells transfected with empty vector and representative
PAR1-Etk/Bmx in Breast Cancer
PLoS ONE | www.plosone.org 14 June 2010 | Volume 5 | Issue 6 | e11135MCF7 clones (e.g., HA-wt hPar1 and HA-hPar1-7A). The protein
levels are compared to a house keeping of b-actin protein levels.
Found at: doi:10.1371/journal.pone.0011135.s004 (2.05 MB TIF)
Figure S5 Immuno histological staining of Etk/Bmx in sections
of mouse mammary tumor xenografts generated following
implantation of MCF7 cells expressing wt hPar1 and variant
constructs. MCF7 cells expressing various hPar1 forms (e.g., wt
hPar1, truncated hPar1,Y 397Z hPar1 and empty vector) were
inoculated into the mammary fat pads of mice. After 45 days the
tumors were excised and embedded with paraffine. Antibodies
directed against Etk/Bmx (Transduction Laboratories; BD
Biosciences, California) were applied on sections derived from
each of the designated treatment. The right panel represents
staining in the absence of anti Etk/Bmx antibodies and presence of
a secondary antibody - only (for controls). As one can note, specific
Etk/Bmx staining is observed in wt hPar1 and particularly strong
staining is noticed in Y397Z hPar1 (Mag 6200). No staining is
observed in either the truncated hPar1 or empty vector sections.
This staining is a representative experiment of three times staining
experiments performed on these mice mammary xenograft
sections.
Found at: doi:10.1371/journal.pone.0011135.s005 (2.05 MB TIF)
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